Contact Us

Professor Earl Hulihan Honored by Marquis Who's Who for Excellence in the Health Care Field

Professor Hulihan has been active in medicine and the pharmaceutical industry since the mid 1970's and is often called upon to speak and serve as chair in many International conferences
  • <strong>Professor Earl Hulihan</strong>
    BANGOR, PA, March 16, 2017 /24-7PressRelease/ -- Professor Earl Hulihan has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Professor Hulihan is Owner of the Professor Earl W. Hulihan Consultancy, an internationally recognized provider of advice and consultation to the global regulatory community, as well as the pharmaceutical, biotech and medical device industry. In addition, Hulihan provides advice and training to regulatory authority personnel within the North American, Latin American, European and APAC communities (16 countries globally). As recently as 2012 and 2016, Hulihan was recognized as an "expert in his field" as well as a "scientific expert" by several of these same regulatory authorities. The knowledge and experiences gained from over 725 'GXP' international Audits is a testament to his domain's strength of knowledge, experience, reputation and character. Professor Hulihan has functioned in the Global GXP Regulatory Environment for over 40 years, primarily in the areas of Quality Assurance, Regulatory Affairs, Clinical Research, Drug Development, Drug Safety and Quality Systems. This includes Senior Quality Assurance positions in the Global Pharmaceutical Environment [Pharma. CRO, and Vendor] as well as over 22 years in Clinical Medicine and Clinical Research at Rutgers, The State University's School of Medicine. Clinical areas of involvement included Cardiovascular, Pulmonary, and Endocrine areas of Medicine as well as Psychiatry.

Professor Hulihan has been active in medicine and the pharmaceutical industry since the mid 1970's and is often called upon to speak and serve as chair in many International conferences. He is active in the Drug Information Association (DIA) and serves on the Editorial Board of the [Guide to Good Clinical Practice and Expert Advisory Panel for Good Clinical Practice: A Question & Answer Reference Guide. Since the mid 1970's, Hulihan has been one of the leaders internationally in Good Clinical Practice, Data Integrity and Data Quality initiatives in Medicine and the pharmaceutical industry. Hulihan is also a Contributing Author to several textbooks; New Drug Approval Process (3rd, 4th, 5th and 6th editions) with chapters on Quality Assurance, China and HIPAA, Good Clinical Practice: A Question & Answer Reference Guide (2008 though 2016 editions) with chapters on cGCPs in Latin America, Canada, Russia and China. As of March 2016, Professor Hulihan is now the Editor - in - Chief of the Good Clinical Practice: A Question & Answer Reference Guide, as well as co-editor of the Global GLP reference book, Computerized Systems in Nonclinical Safety Assessment: Current Concepts in Validation and Compliance (a.k.a. Red Apple II) (2008) and Editor of the Global GCP reference book, Computerized Systems in Clinical Research: Current Quality and Data Integrity Concepts (a.k.a. Peach) and reviewer for the Journal of Medical Systems for many years. He has also authored numerous journal articles during his career. During the early 1970's, Hulihan collaborated with one of the fathers of sports medicine, Dr. Hans Kraus, in the development of a new global clinical program for the "Prevention and Treatment of Back Ache, Stress and Tension." Also, during the 1970's, Hulihan collaborated in writing the Special Olympics Program (an internationally recognized program for persons with intellectual disabilities). The Joseph P. Kennedy Foundation acknowledged Hulihan with a special award. He has achieved other significant honors from diverse International organizations including Who's Who (Computer industry as well as Executives and Professionals), the American Heart Association's Distinguished Honors Award and the Drug Information Association's two highest honors - the prestigious Distinguished Service and the Founders Service Awards. Professor Hulihan currently serves as a Professor with China Pharmaceutical University (Nanjing, China), as an Associate Professor with Rutgers University School of Medicine (USA) and a Visiting Professor with the prestigious Shanghai University of Traditional Chinese Medicine (China). In 2010, the Professor was honored with a Professorship to China's Food and Drug Administration's Institute of Executive Development. Professor Hulihan is the First Westerner ever appointed to a Professorship at either SUTCM or the CFDA Institute.

About Marquis Who's Who :
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com.


# # #

Read more Press Releases from Fred Marks:


Comment on this story...

Share This Story


Email this Story

Contact Information


Fred Marks
Marquis Who's Who Ventures LLC

Berkeley Heights, NJ
USA
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us:

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.